FR2840905B1 - Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers - Google Patents
Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancersInfo
- Publication number
- FR2840905B1 FR2840905B1 FR0207212A FR0207212A FR2840905B1 FR 2840905 B1 FR2840905 B1 FR 2840905B1 FR 0207212 A FR0207212 A FR 0207212A FR 0207212 A FR0207212 A FR 0207212A FR 2840905 B1 FR2840905 B1 FR 2840905B1
- Authority
- FR
- France
- Prior art keywords
- mab
- antibody
- aurora
- optionally
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 239000003550 marker Substances 0.000 abstract 2
- 102000004000 Aurora Kinase A Human genes 0.000 abstract 1
- 108090000461 Aurora Kinase A Proteins 0.000 abstract 1
- 108050006400 Cyclin Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000001114 immunoprecipitation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207212A FR2840905B1 (fr) | 2002-06-12 | 2002-06-12 | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
| AT03760023T ATE420115T1 (de) | 2002-06-12 | 2003-06-12 | Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs |
| AU2003255671A AU2003255671A1 (en) | 2002-06-12 | 2003-06-12 | Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers |
| EP03760023A EP1511771B1 (fr) | 2002-06-12 | 2003-06-12 | Anticorps monoclonal anti-aurora-a, son procede d obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
| DE60325725T DE60325725D1 (de) | 2002-06-12 | 2003-06-12 | Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs |
| US10/517,645 US7514231B2 (en) | 2002-06-12 | 2003-06-12 | Anti-aurora-A monoclonal antibody, method for obtaining same and uses thereof for diagnosing and treating cancers |
| CA2489214A CA2489214C (fr) | 2002-06-12 | 2003-06-12 | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
| PCT/FR2003/001772 WO2003106500A1 (fr) | 2002-06-12 | 2003-06-12 | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
| JP2004513330A JP4555681B2 (ja) | 2002-06-12 | 2003-06-12 | 抗オーロラ−ａモノクローナル抗体、該抗体を得る方法、並びに癌の診断および処置のための該抗体の使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207212A FR2840905B1 (fr) | 2002-06-12 | 2002-06-12 | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2840905A1 FR2840905A1 (fr) | 2003-12-19 |
| FR2840905B1 true FR2840905B1 (fr) | 2006-07-07 |
Family
ID=29595167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0207212A Expired - Lifetime FR2840905B1 (fr) | 2002-06-12 | 2002-06-12 | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7514231B2 (enExample) |
| EP (1) | EP1511771B1 (enExample) |
| JP (1) | JP4555681B2 (enExample) |
| AT (1) | ATE420115T1 (enExample) |
| AU (1) | AU2003255671A1 (enExample) |
| CA (1) | CA2489214C (enExample) |
| DE (1) | DE60325725D1 (enExample) |
| FR (1) | FR2840905B1 (enExample) |
| WO (1) | WO2003106500A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2239692C (en) * | 1995-12-18 | 2008-12-16 | Sugen, Inc. | Diagnosis and treatment of aur-1 and/or aur-2 related disorders |
-
2002
- 2002-06-12 FR FR0207212A patent/FR2840905B1/fr not_active Expired - Lifetime
-
2003
- 2003-06-12 WO PCT/FR2003/001772 patent/WO2003106500A1/fr not_active Ceased
- 2003-06-12 DE DE60325725T patent/DE60325725D1/de not_active Expired - Lifetime
- 2003-06-12 CA CA2489214A patent/CA2489214C/fr not_active Expired - Lifetime
- 2003-06-12 EP EP03760023A patent/EP1511771B1/fr not_active Expired - Lifetime
- 2003-06-12 AT AT03760023T patent/ATE420115T1/de not_active IP Right Cessation
- 2003-06-12 AU AU2003255671A patent/AU2003255671A1/en not_active Abandoned
- 2003-06-12 JP JP2004513330A patent/JP4555681B2/ja not_active Expired - Lifetime
- 2003-06-12 US US10/517,645 patent/US7514231B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003106500A1 (fr) | 2003-12-24 |
| EP1511771B1 (fr) | 2009-01-07 |
| ATE420115T1 (de) | 2009-01-15 |
| CA2489214C (fr) | 2013-08-06 |
| CA2489214A1 (fr) | 2003-12-24 |
| EP1511771A1 (fr) | 2005-03-09 |
| US20070117163A1 (en) | 2007-05-24 |
| JP4555681B2 (ja) | 2010-10-06 |
| DE60325725D1 (de) | 2009-02-26 |
| FR2840905A1 (fr) | 2003-12-19 |
| AU2003255671A1 (en) | 2003-12-31 |
| US7514231B2 (en) | 2009-04-07 |
| JP2006513135A (ja) | 2006-04-20 |
| AU2003255671A8 (en) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sato et al. | Neutrophil elastase and cancer | |
| Moretti et al. | β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines | |
| Walsh et al. | Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer | |
| van Oosterwijk et al. | Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets | |
| JP2009525478A5 (enExample) | ||
| RU2007139912A (ru) | Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата | |
| DE69717664D1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
| ZA200202942B (en) | Elisa for VEGF. | |
| MX2009003562A (es) | Ensayo elisa para la deteccion de vegf. | |
| DE50306067D1 (de) | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern | |
| ATE198513T1 (de) | Ptpalpha-bestimmung in der tumordiagnose und - prognose | |
| ATE419375T1 (de) | Amplifizierung von cyp24 und anwendung dafür | |
| Rasmuson et al. | Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma | |
| FR2919061B1 (fr) | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal. | |
| FR2840905B1 (fr) | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers | |
| IL190401A0 (en) | Antibodies against april as biomarkers for early prognosis of lymphoma patients | |
| EP1276771A4 (en) | Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample | |
| WO2004040312A3 (fr) | Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie | |
| AU2002306568A1 (en) | Forms of prostate specific antigens and methods for their detection | |
| JP2006513135A5 (enExample) | ||
| Schutter et al. | The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy±chemotherapy | |
| Altaras et al. | Detection of tumor circulating cells by cytokeratin-20 in the blood of patients with granulosa cell tumors | |
| RU2275636C1 (ru) | Способ прогнозирования рецидивов в мочевой пузырь у больных раком почечной лоханки и мочеточника после радикального хирургического лечения | |
| DE60326269D1 (de) | Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika | |
| Paltuev et al. | Automated analysis of cell density in breast cancer as an additional method of increasing objectivity and accuracy of breast cancer prognosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TQ | Partial transmission of property | ||
| PLFP | Fee payment |
Year of fee payment: 15 |
|
| PLFP | Fee payment |
Year of fee payment: 16 |
|
| PLFP | Fee payment |
Year of fee payment: 17 |
|
| PLFP | Fee payment |
Year of fee payment: 19 |
|
| PLFP | Fee payment |
Year of fee payment: 20 |